Literature DB >> 10654914

Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue.

C G Stief1, S Uckert, A J Becker, W Harringer, M C Truss, W G Forssmann, U Jonas.   

Abstract

OBJECTIVES: To further investigate the mechanism of action of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase 5 (PDE5), that has been proved to be effective in the treatment of male erectile dysfunction. We assessed the effects of sildenafil on the in vitro formation of cGMP and cyclic adenosine monophosphate (cAMP) in isolated human corpus cavernosum and cardiac muscle.
METHODS: Isolated segments of human corpus cavernosum and cardiac muscle were exposed to increasing concentrations of sildenafil. The dose-dependent accumulation of cGMP and cAMP was determined in the tissue samples by means of radioimmunoassays. Responses of the isolated tissue preparations to sildenafil were compared with those obtained with the reference compounds sodium nitroprusside, forskolin, and milrinone.
RESULTS: In the concentration range 0.01 to 1 microM, there was only a minor effect of sildenafil on cGMP levels in isolated human cavernous and cardiac tissues. In contrast, sildenafil was found to increase cAMP significantly in both cavernous and cardiac tissue in physiologic and supraphysiologic concentrations. The stimulation of cAMP by sildenafil was more pronounced in cavernous than in cardiac tissue. Concentrations of cGMP in the cardiac strips were unaltered by milrinone; cAMP was stimulated starting at a concentration of 0.05 microM. In the range of 0.1 to 1.0 microM, the in vitro effect of sildenafil on cAMP levels in the cardiac samples was almost equivalent to that of milrinone.
CONCLUSIONS: Our findings provide a potential mechanism for the cardiovascular side effects that have been reported with sildenafil use, highlighting the fact that a "cross-talk" between cGMP and cAMP-dependent signal transduction pathways might exist in human cavernous and cardiac muscle that may be of pharmacologic significance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10654914     DOI: 10.1016/s0090-4295(99)00371-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

1.  Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.

Authors:  Eginhard Waldkirch; Stefan Uckert; Hüseyin Yildirim; Michael Sohn; Udo Jonas; Christian G Stief; Karl-Erik Andersson; Petter Hedlund
Journal:  World J Urol       Date:  2005-11-15       Impact factor: 4.226

2.  Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.

Authors:  S Oger; D Behr-Roussel; D Gorny; T Lebret; P Validire; X Cathelineau; L Alexandre; F Giuliano
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Relaxant effect and possible mechanism of 17-nor-subincanadine E in rabbit corpora cavernosa.

Authors:  Otacilio D Benvindo; Nilberto Rf Nascimento; Claudia F Santos; Manasses C Fonteles; Edilberto R Silveira; Daniel E Uchoa; Adriana R Campos; Karina Ma Cunha; Flavia A Santos; Vietla S Rao
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

Review 4.  Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2004-12

Review 5.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  [Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].

Authors:  H Derouet; J Osterhage; H Sittinger
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

Review 7.  The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

Authors:  George T Kedia; Stefan Uckert; Udo Jonas; Markus A Kuczyk; Martin Burchardt
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

Review 8.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

9.  Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.

Authors:  Stefan Uckert; Petter Hedlund; Eginhard Waldkirch; Michael Sohn; Udo Jonas; Karl-Erik Andersson; Christian G Stief
Journal:  World J Urol       Date:  2004-03-26       Impact factor: 4.226

Review 10.  A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.

Authors:  D Vitezic
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.